EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis

Minori Sasakura, Hitoshi Urakami, Kota Tachibana, Kenta Ikeda, Ken-Ichi Hasui, Yoshihiro Matsuda, Ko Sunagawa, Daisuke Ennishi, Shuta Tomida, Shin Morizane

Allergology International · 2024

DOI: 10.1016/j.alit.2023.12.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergology International, 2024. Verfasst von Minori Sasakura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Azetidines, Benzophenones, Dermatitis, Atopic, Isoxazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi K.K., Maruho, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Selective activator protein (AP)-1 inhibitors are potentially promising therapeutic agents for atopic dermatitis (AD) because AP-1 is an important regulator of skin inflammation. However, few studies have investigated the effect of topical application of AP-1 inhibitors in treating inflammatory skin disorders. METHODS: Immunohistochemistry was conducted to detect phosphorylated AP-1/c-Jun expression of skin lesions in AD patients. In the in vivo study, 1 % T-5224 ointment was topically applied for 8 days to the ears of 2,4 dinitrofluorobenzene challenged AD-like dermatitis model mice. Baricitinib, a conventional therapeutic agent Janus kinase (JAK) inhibitor, was also topically applied. In the in vitro study, human epidermal keratinocytes were treated with T-5224 and stimulated with AD-related cytokines. RESULTS: AP-1/c-Jun was phosphorylated at skin lesions in AD patients. In vivo, topical T-5224 application inhibited ear swelling (P < 0.001), restored filaggrin (Flg) expression (P < 0.01), and generally suppressed immune-related pathways. T-5224 significantly suppressed Il17a and l17f expression, whereas baricitinib did not. Baricitinib suppressed Il4, Il19, Il33 and Ifnb expression, whereas T-5224 did not. Il1a, Il1b, Il23a, Ifna, S100a8, and S100a9 expression was cooperatively downregulated following the combined use of T-5224 and baricitinib. In vitro, T-5224 restored the expression of FLG and loricrin (LOR) (P < 0.05) and suppressed IL33 expression (P < 0.05) without affecting cell viability and cytotoxicity. CONCLUSIONS: Topical T-5224 ameliorates clinical manifestations of AD-like dermatitis in mice. The effect of this inhibitor is amplified via combined use with JAK inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesBenzophenonesDermatitis, AtopicIsoxazolesPurinesPyrazolesSulfonamidesAnimalsHumansMiceCytokinesInflammationInterleukin-33SkinTranscription Factor AP-1

Stichwörter der Autor:innen

AP-1 inhibitorAtopic dermatitisBaricitinibT-5224Topical application

Substanzen

3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acidAzetidinesbaricitinibBenzophenonesCytokinesInterleukin-33IsoxazolesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Electronic address: zanemori@cc.okayama-u.ac.jp.

Förderung

  • Sanofi K.K.
  • Maruho
  • AbbVie
  • Eli Lilly Japan
  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Sasakura, M., Urakami, H., Tachibana, K., Ikeda, K., Hasui, K. I., Matsuda, Y., Sunagawa, K., Ennishi, D., Tomida, S., & Morizane, S. (2024). Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis. Allergology International. https://doi.org/10.1016/j.alit.2023.12.006

Vancouver

Sasakura M, Urakami H, Tachibana K, Ikeda K, Hasui KI, Matsuda Y, et al. Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis. Allergology International. 2024. doi:10.1016/j.alit.2023.12.006

BibTeX
@article{Sasakura2024,
  author = {Sasakura, Minori and Urakami, Hitoshi and Tachibana, Kota and Ikeda, Kenta and Hasui, Ken-Ichi and Matsuda, Yoshihiro and Sunagawa, Ko and Ennishi, Daisuke and Tomida, Shuta and Morizane, Shin},
  title = {Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis},
  journal = {Allergology International},
  year = {2024},
  doi = {10.1016/j.alit.2023.12.006}
}
Kostenlos starten →